RB1 deletion
|
Prostate Cancer
|
RB1 deletion
|
Prostate Cancer
|
abiraterone acetate Resistant: B - Late Trials
|
abiraterone acetate Resistant: B - Late Trials
|
RB1 deletion
|
Prostate Cancer
|
RB1 deletion
|
Prostate Cancer
|
enzalutamide capsule Resistant: B - Late Trials
|
enzalutamide capsule Resistant: B - Late Trials
|
RB1 deletion
|
Hormone Receptor Positive Breast Cancer
|
RB1 deletion
|
Hormone Receptor Positive Breast Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
RB1 deletion
|
Melanoma
|
RB1 deletion
|
Melanoma
|
palbociclib Resistant: D – Preclinical
|
palbociclib Resistant: D – Preclinical
|
RB1 deletion
|
Mesothelioma
|
RB1 deletion
|
Mesothelioma
|
BI 6727 Sensitive: D – Preclinical
|
BI 6727 Sensitive: D – Preclinical
|
RB1 deletion
|
Mesothelioma
|
RB1 deletion
|
Mesothelioma
|
MLN8237 Sensitive: D – Preclinical
|
MLN8237 Sensitive: D – Preclinical
|
RB1 deletion
|
Mantle Cell Lymphoma
|
RB1 deletion
|
Mantle Cell Lymphoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
RB1 deletion
|
Ovarian Cancer
|
RB1 deletion
|
Ovarian Cancer
|
SRA515 Sensitive: D – Preclinical
|
SRA515 Sensitive: D – Preclinical
|
RB1 deletion
|
Ovarian Cancer
|
RB1 deletion
|
Ovarian Cancer
|
palbociclib + SRA515 Sensitive: D – Preclinical
|
palbociclib + SRA515 Sensitive: D – Preclinical
|